Autolus Therapeutics (AUTL)

• Market cap: $375M
• 1 day: 7.63%
• 5 days: -9.62%
• 1 month: -9.03%
• 3 months: -35.91%
• 6 months: -64.75%
• Year to date: -46.39%
• 1 year: -61.68%
• 5 years: -85.03%
• 10 years: -94.36%
• Sector: Healthcare
• Industry: Biotechnology

About: Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Employees: 647

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

53% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 15

7% more funds holding

Funds holding: 99 [Q3] → 106 (+7) [Q4]

7% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 30

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

3.88% less ownership

Funds ownership: 67.12% [Q3] → 63.24% (-3.88%) [Q4]

39% less capital invested

Capital invested by funds: $648M [Q3] → $395M (-$253M) [Q4]

77% less call options, than puts

Call options by funds: $84K | Put options by funds: $362K

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 326% upside
• Avg. target: $8.67 515% upside
• High target: $10 609% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Needham Gil Blum 18% 1-year accuracy 29 / 158 met price target	609% upside $10	Buy Reiterated	10 Apr 2025
Truist Securities Asthika Goonewardene 30% 1-year accuracy 7 / 23 met price target	609% upside $10	Buy Maintained	1 Apr 2025
Wells Fargo Yanan Zhu 13% 1-year accuracy 2 / 16 met price target	326% upside $6	Overweight Maintained	21 Mar 2025